PFE SEC Filings
SEC filings for PFE. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-QAIPfizer reports modest operational revenue growth (1% in Q2, 2% YTD) and strong performance from key products, but a GAAP pre-tax loss of $653 million in Q2 driven by impairments and legal charges. | Aug 4, 2026 | 0000078003-26-000095EDGAR |
| 10-Q | May 5, 2026 | 0000078003-26-000054EDGAR |
| 10-QAIPfizer's Q3 2025 MD&A is a mixed, largely factual account: revenue fell 6% on COVID product declines, offset by growth in Eliquis, Vyndaqel and oncology, cost savings and a strong liquidity position. | Nov 4, 2025 | 0000078003-25-000150EDGAR |
SEC filings for companies related to PFE
Never miss a PFE filing.
Get an email when PFE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.